Aspire BioPharma is trading 5.52% higher at $8.65, likely reflecting broader biotech strength; no company-specific announcement, filing, earnings release, or regulatory catalyst was identified for September 23, 2026. - Biotechnology stocks are advancing broadly, with XBI up 2.07% during regular trading. - The latest identified filing, covering a name change and $10 million buyback authorization, was dated September 8, not today.